Jacob Vogelstein is a Co-Founder & Managing Partner of Catalio Capital Management, LP. He is primarily responsible for managing the firm and for making investments in breakthrough biomedical technology companies founded by world renowned scientist-entrepreneurs. He also serves on the Nexus Investment Committee and the firmwide Management Committee.
Jacob currently serves on the Board of Directors of Cage Pharmaceuticals, Entos AI, Haystack Oncology, Boost Neuroscience, Pheast Therapeutics, ManaT bio, and Proto Axiom.
Prior to founding Catalio, he was a General Partner at Camden Partners Holdings, LLC, a private equity firm, where he focused on making biomedical technology investments. Prior to joining Camden, Jacob was a founding partner of the seed-stage venture capital firm Gamma 3, LLC, and a Program Manager at the Intelligence Advanced Research Projects Activity, where he made investments in high-risk, high-reward research to benefit the US Intelligence Community. Earlier in his career, Jacob served on the faculty at Johns Hopkins University, at both the Applied Physics Laboratory and the Whiting School of Engineering.
Jacob has received widespread recognition for his innovative work in biomedical engineering over the past decade. In 2017, he was awarded the Presidential Early Career Award in Science and Engineering, which is the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their careers. He has been an invited speaker for diverse audiences ranging from BBC News to President Obama’s Council of Advisors on Science and Technology, has authored over 50 peer-reviewed publications, and has multiple patents in the fields of neuroprosthetics and brain-machine interfaces.
Jacob earned his BSc. degree in Bio-Electrical Engineering from Brown University and his Ph.D. degree in Biomedical Engineering from the Johns Hopkins University School of Medicine.